- Short Report
- Open Access
Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells
© Zou et al.; licensee BioMed Central Ltd. 2012
- Received: 28 February 2012
- Accepted: 28 March 2012
- Published: 28 March 2012
Dihydropyridine calcium channel blockers (CCBs) are more effective in reducing carotid intima-media thickness (IMT) than other classes of antihypertensive drugs due to their vascular effects. However, the mechanism remains to be elucidated.
Ox-LDL induced HUVSMCs proliferation in a time- and dose-dependent manner. When pretreated with three CCBs before 50 μg/ml ox-LDL stimulation, 30 μM lacidipine and 3 μM amlodipine exhibited 27% and 18% decrease of pro-proliferative effect induced by ox-LDL, whereas (S-)-amlodipine did not have any anti-proliferative effect. 30 μM lacidipine inhibited about two-thirds of the ox-LDL induced ROS production in HUVSMCs, whereas amlodipine and (S-)-amlodipine did not have influence on ROS production. The MAPKs pathway inhibitors inhibited the ox-LDL induced proliferation of HUVSMCs.
Our study has demonstrated that lipophilic CCBs, such as lacidipine may inhibit ox-LDL induced proliferation and oxidative stress of VSMCs, and that the ROS-MAPKs pathway might be involved in the mechanism.
- Calcium channel blockers
- Oxidative stress
- Oxidized low-density lipoprotein
- Vascular smooth muscle cells
In our previous meta-analysis, we found that calcium channel blockers (CCBs), mainly the dihydropyridine type, were more effective in reducing carotid intima-media thickness (IMT) than other classes of antihypertensive drugs such as diuretics, β-blockers, and angiotensin-converting enzyme (ACE) inhibitors . This advantage of CCBs might contribute to their superiority in the prevention of stroke that had been repeatedly shown in previous studies . However, the mechanism for the vascular advantage of CCBs remains to be elucidated.
IMT is a measure of vascular hypertrophy, which is in part the consequence of media thickening. It is known that the oxidized low-density lipoprotein (ox-LDL) cholesterol may induce oxidative stress of vascular smooth muscle cells (VSMCs) by activating the mitogen-activated protein kinases (MAPKs) pathway, and in turn promote proliferation of VSMCs [3, 4] and hence vascular hypertrophy. The oxidative mechanism may increase formation of intracellular reactive oxygen species (ROS), which may behave as intracellular second messengers and modulate expression of genes that influence the development of vascular lesions . We hypothesized that CCBs might exert their vascular protective effect via the oxidative stress pathway in VSMCs.
Several long-acting CCBs have been studied for their vascular effects, and are frequently used in clinical practice in many countries, such as amlodipine , lacidipine  and azelnidipine . These long-acting CCBs are indifferent in the blood pressure lowering effect, but different in lipophilicity and hence the binding affinity with the calcium channels inside the lipophilic cell membrane. Lacidipine is highly lipophilic and has long-term blood pressure lowering effect, even though its terminal elimination half-life (t1/2z) is approximately 6–10.8 h . The lipophilic property of lacidipine can also be important in vascular protection, because it apparently may interact with cells in the absence of L-type calcium channels, and give lacidipine vascular protection effects independent of its actions on blood pressure . Amlodipine is also lipophilic  but less than lacidipine . Amlodipine has two enantiomers. It is known that only the (S-)-isomer of amlodipine has blood pressure lowering effect, and has recently been available in the Chinese market as a separate drug from amlodipine. However, there is some evidence that the (R+)-isomer of amlodipine is not a simple bystander, but might exert vascular protective effect, and play a role in the peculiar protective effect of amlodipine [10, 11], as repeatedly shown in large randomized controlled trials in hypertension  and coronary artery disease . We therefore investigated the effect of lacidipine, amlodipine and (S-)-amlodipine on the ox-LDL induced proliferation and oxidative stress of VSMCs.
Pro-proliferation of ox-LDL
Effects of CCBs on cell proliferation
Effects of CCBs on cell ROS production
Effects of MAPKs inhibitors on cell proliferation
Our study has demonstrated an anti-proliferative and anti-oxidative effect of the lipophilic CCBs on HUVSMCs. The most lipophilic CCB lacidipine may inhibit proliferation and oxidative stress of VSMCs. Amlodipine also inhibits proliferation but does not influence oxidative stress, whereas its (S-)-isomer, (S-)-amlodipine, does not have anti-proliferative, nor anti-oxidative effect. Our finding may have clinical implications, because enhanced proliferation of VSMCs and change from the contractile to proliferative/secretory phenotype may contribute to the pathogenesis of atherosclerosis, restenosis after angioplasty, and graft atherosclerosis after coronary transplantation [12, 13], and because intracellular ROS regulates phenotypic differentiation of VSMC .
Similar anti-proliferative and anti-oxidative effects of lacidipine had been observed on other cell lines. In human umbilical vein endothelial cells, lacidipine might decrease NF-κB-mediated and ox-LDL induced adhesion molecule expression . This effect of lacidipine might be the consequence of its influence on the intracellular ROS formation induced by ox-LDL .
In keeping with several previous studies [17–19], our study showed that amlodipine might also inhibit VSMC proliferation. However, we only observed a weak and nonsignificant anti-oxidative effect of amlodipine, which was different from the results of previous studies [19, 20]. Other mechanisms than the anti-oxidative effect might be involved in the anti-proliferative effect of amlodipine, such as, calcium signaling through ERK1/2 cascade, nitric oxide (NO) production, modulation of matrix metalloproteinases activity, etc. .
At least one previous study suggested that the vascular effect of amlodipine was attributable to the action of its (R+)-isomer, which had no effect on blood pressure . In endothelial cells, which had no calcium channels, (R+)-amlodipine, but not (S-)-amlodipine might activate NO synthase and promoted the production of NO [10, 11]. In our study in VSMCs, (S-)-amlodipine did not inhibit ox-LDL induced proliferation and oxidative stress of HUVSMCs. The distinct effect of amlodipine and (S-)-amlodipine is not understood. It is possible that (R+)-amlodipine and (S-)-amlodipine have different lipophilicities, and hence have different vascular effects. Taking into account the strong effect of the highly lipophilic CCB lacidipine, this explanation is very likely.
We also studied the role of ROS in the proliferation of VSMCs by the use of NAC, a ROS scavenger, and the role of the MAPKs signaling pathway by the use of the distinct inhibitors of this pathway. Our finding of these experiments suggested that the ROS-MAPKs pathway might be one of mechanisms for the effect of CCBs on proliferation of VSMCs. This mechanism may also explain why lacidipine has strong anti-proliferative effect. The dihydropyridine ring of the higher lipophilic CCBs, such as lacidipine, facilitates proton-donating and resonance-stabilization mechanisms that quench the free radical reaction, thereby blocking the peroxidation process and ROS production .
In conclusion, our study has demonstrated that lipophilic CCBs, such as lacidipine may inhibit ox-LDL induced proliferation and oxidative stress of VSMCs. Although our finding is in line with the results of previous animal studies [22, 23] and human research [6, 24] on the vascular effects of CCBs, further studies in animals and humans are still required to compare these long-acting CCBs at similar blood pressure lowering dosages.
Chemicals and reagents
In our experiments, three CCBs were employed. Lacidipine (courtesy of GlaxoSmithKline China, Shanghai, China) was dissolved in the mixture of Tween-80 and ethanol (2:8). Amlodipine (a 1:1 mixture of two enantiomers; courtesy of Pfizer China, Shanghai, China) and (S-)-amlodipine (courtesy of Shihuida, Changchun, China) were all dissolved in dimethyl sulfoxide (DMSO). Ox-LDL (about 1.6 mg/ml) was purchased from UnionBiol (Beijing, China), and the extent of the LDL oxidation was determined by measuring the levels of thiobarbituric acidreactive substances (TBARS). SB-202190 (an inhibitor of p38 MAPK), SP-600125 (an inhibitor of JNK) and U-0126 (an inhibitor of MEK) were purchased from CalBiochem (San Diego, California, USA). The following chemicals were purchased from Sigma-Aldrich (Shanghai, China): Angiotensin II, NAC, 2′, 7′-dichlorofluorescin diacetate (DCFH-DA), DMSO and Tween 80. We also purchased cell proliferation reagents WST-1 (Roche, Basel, Switzerland), fetal bovine serum (FBS; Invitrogen, California, USA) and Typan Blue (Beyotime, Jiangsu, China).
Human umbilical vein smooth muscle cells (HUVSMCs) were obtained from the Health Protection Agency Culture Collections (Porton Down, Salisbury, UK). Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) of high glucose supplemented with 10% FBS without antibiotics. The cells were maintained 37°C in a 5% CO2 incubator. The medium was changed every 2 days. Cells were digested with 0.25% trypsin and 0.02% EDTA when cells reached 70-80% confluency, and were serum-deprived in DMEM with 0.1% FBS for 24 h before each experiment when cells reached 60-70% confluency. After serum deprivation, the cells were treated with reagents, pharmacological inhibitors and treatment drugs as noted in the figure legends. During the period of experiment, medium with 0.4% FBS was employed for the maintenance of cell viability. Trypan blue exclusion test was applied to detect cell viability. On our experimental conditions, cell viability after each experiment was always greater than 95%.
Cell proliferation assay
In order to determine the effect of a compound on cell growth, serum-starved cells at a density of 1 × 104 cells/well were incubated on 24-well plates for 24 h followed by another 2.5 h of incubation with water-soluble tetrazolium salts (WST-1). The tetrazolium salts were cleaved to soluble formazan by intracellular mitochondrial dehydrogenases in the sample. This augmentation in enzyme activity led to an increase in the amount of formed formazan dye, which was directly correlated with the number of proliferative cells in the culture. Quantification of the formazan dye produced by metabolically active cells was measured at 440 nm wavelengths by scanning the multiwell spectrophotometer. Because various concentrations of 2 different solvents were used for these experiments, we set a solvent-only control group for each of the 2 different solvents at higher concentrations.
Detection of intracellular ROS
DCFH-DA is a dye that allows monitoring of ROS by the fluorescence microplate spectrophotometer. This method is based on the oxidation of DCFH-DA by ROS, resulting in the formation of the fluorescent compound DCF. Serum-starved cells in 24-well plates were preincubated with the three CCBs and NAC for 30 min as described above, and ox-LDL (50 μg/ml) was then added to the medium for 1.5 h. DCFH-DA (10 μM) probe was then added and incubated for another 30 min. Thereafter, cells were immediately washed twice with PBS and added to 400 μl DMEM. The fluorescent intensity was read five times and averaged. The excitation wavelength was 504 nm, and the emission wavelength was 529 nm.
Values were mean ± SD. Means were compared by one-way ANOVA with the post hoc test for multiple comparisons (Dunnett’s test for comparison of a single control or Bonferroni correction for pairwise comparisons). P < 0.05 was considered statistically significant.
The study was partially supported by an unrestricted grant from GSK China (Shanghai) and Beijing Baimeite Pharmaceutical Company. The study was also financially supported by grants from the National Natural Science Foundation of China (30871360 and 30871081), the Ministry of Science and Technology (2006BAI01A03 and a grant for China-European Union collaborations ) and the Ministry of Education (NCET-09-0544), Beijing, China, the Shanghai Commissions of Science and Technology (07JC14047 and the “Rising Star” program 06QA14043) and Education (07ZZ32 and the “Dawn” project 08SG20), Shanghai Jiaotong University School of Medicine (a grant of Distinguished Young Investigators to Yan Li), and the European Union (LSHM-CT-2006-037093 and HEALTH-F4-2007-201550).
- Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M: Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006, 37: 1933-1940. 10.1161/01.STR.0000227223.90239.13.PubMedView ArticleGoogle Scholar
- Wang JG, Li Y, Franklin SS, Safar M: Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007, 50: 181-188. 10.1161/HYPERTENSIONAHA.107.089763.PubMedView ArticleGoogle Scholar
- Yang CM, Chien CS, Hsiao LD, Pan SL, Wang CC, Chiu CT, Lin CC: Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol. 2001, 132: 1531-1541. 10.1038/sj.bjp.0703976.PubMedPubMed CentralView ArticleGoogle Scholar
- Chahine MN, Blackwood DP, Dibrov E, Richard MN, Pierce GN: Oxidized LDL affects smooth muscle cell growth through MAPK-mediated actions on nuclear protein import. J Mol Cell Cardiol. 2009, 46: 431-441. 10.1016/j.yjmcc.2008.10.009.PubMedView ArticleGoogle Scholar
- Finkel T: Oxygen radicals and signaling. Curr Opin Cell Biol. 1998, 10: 248-253. 10.1016/S0955-0674(98)80147-6.PubMedView ArticleGoogle Scholar
- Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000, 102: 1503-1510. 10.1161/01.CIR.102.13.1503.PubMedView ArticleGoogle Scholar
- Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002, 106: 2422-2427. 10.1161/01.CIR.0000039288.86470.DD.PubMedView ArticleGoogle Scholar
- Ogawa S, Mori T, Nako K, Ito S: Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008, 31: 1147-1155. 10.1291/hypres.31.1147.PubMedView ArticleGoogle Scholar
- McCormack PL, Wagstaff AJ: Lacidipine: a review of its use in the management of hypertension. Drugs. 2003, 63: 2327-2356. 10.2165/00003495-200363210-00008.PubMedView ArticleGoogle Scholar
- Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH: Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+enantiomer of amlodipine. J Cardiovasc Pharmacol. 2002, 39: 208-214. 10.1097/00005344-200202000-00007.PubMedView ArticleGoogle Scholar
- Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R: Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology. 2004, 70: 39-45. 10.1159/000074241.PubMedView ArticleGoogle Scholar
- Sanz-Gonzalez SM, Poch E, Perez-Roger I, Diez-Juan A, Ivorra C, Andres V: Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease. Front Biosci. 2000, 5: D619-D628. 10.2741/sanz.PubMedView ArticleGoogle Scholar
- Doran AC, Meller N, McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008, 28: 812-819. 10.1161/ATVBAHA.107.159327.PubMedPubMed CentralView ArticleGoogle Scholar
- Su B, Mitra S, Gregg H, Flavahan S, Chotani MA, Clark KR, Goldschmidt-Clermont PJ, Flavahan NA: Redox regulation of vascular smooth muscle cell differentiation. Circ Res. 2001, 89: 39-46. 10.1161/hh1301.093615.PubMedView ArticleGoogle Scholar
- Cominacini L, Garbin U, Fratta PA, Paulon T, Davoli A, Campagnola M, Marchi E, Pastorino AM, Gaviraghi G, Lo CV: Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens. 1997, 15: 1633-1640. 10.1097/00004872-199715120-00065.PubMedView ArticleGoogle Scholar
- Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Pastorino AM, Gaviraghi G, Lo CV: Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J Hypertens. 1998, 16: 1913-1919. 10.1097/00004872-199816121-00010.PubMedView ArticleGoogle Scholar
- Ziesche R, Petkov V, Lambers C, Erne P, Block LH: The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 2004, 18: 1516-1523. 10.1096/fj.04-1662com.PubMedView ArticleGoogle Scholar
- Ohba T, Watanabe H, Murakami M, Radovanovic M, Iino K, Ishida M, Tosa S, Ono K, Ito H: Amlodipine inhibits cell proliferation via PKD1-related pathway. Biochem Biophys Res Commun. 2008, 369: 376-381. 10.1016/j.bbrc.2008.02.075.PubMedView ArticleGoogle Scholar
- Mason RP, Marche P, Hintze TH: Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003, 23: 2155-2163. 10.1161/01.ATV.0000097770.66965.2A.PubMedView ArticleGoogle Scholar
- Mason RP, Walter MF, Trumbore MW, Olmstead EG, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 1999, 31: 275-281. 10.1006/jmcc.1998.0867.PubMedView ArticleGoogle Scholar
- Godfraind T: Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond, B, Biol Sci. 2005, 360: 2259-2272. 10.1098/rstb.2005.1774.PubMedPubMed CentralView ArticleGoogle Scholar
- Cristofori P, Crivellente F, Campagnola M, Pasini AF, Garbin U, Rigoni A, Tosetti M, Turton J, Faustinelli I, Cominacini L: Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation. Int J Exp Pathol. 2004, 85: 105-114. 10.1111/j.0959-9673.2004.00375.x.PubMedPubMed CentralView ArticleGoogle Scholar
- Keles MS, Bayir Y, Suleyman H, Halici Z: Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats. Mol Cell Biochem. 2009, 328: 109-117. 10.1007/s11010-009-0080-y.PubMedView ArticleGoogle Scholar
- Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, Parati G, Facchetti R, Mancia G: Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009, 120: 1084-1090. 10.1161/CIRCULATIONAHA.108.773119.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.